Effects of a beta-adrenergic receptor blocker in myocardial infarction treated for one year from onset.
D000526:Alprenolol / Q000627:therapeutic use; D000605:Amino Alcohols / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000453:epidemiology; D001794:Blood Pressure / Q000187:drug effects; D005117:Cardiac Complexes, Premature / Q000453:epidemiology; D002986:Clinical Trials as Topic; D004417:Dyspnea / Q000453:epidemiology; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000453:epidemiology; D006801:Humans; D007511:Ischemia; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000534:rehabilitation; D005996:Nitroglycerin / Q000627:therapeutic use; D010101:Oxygen Consumption / Q000187:drug effects; D010359:Patient Readmission; D005082:Physical Exertion; D012119:Respiration / Q000187:drug effects; D013565:Sympatholytics / Q000627:therapeutic use*; D013997:Time Factors
D000605:Amino Alcohols; D013565:Sympatholytics; D000526:Alprenolol; D005996:Nitroglycerin